Peyona (previously Nymusa)

RSS

caffeine

Authorised
This medicine is authorised for use in the European Union.

Overview

Peyona is a stimulant medicine used for treating apnoea of prematurity, a condition in which babies born prematurely stop breathing for longer than 20 seconds.

Peyona contains the active substance caffeine citrate.

This EPAR was last updated on 16/09/2020

Authorisation details

Product details
Name
Peyona (previously Nymusa)
Agency product number
EMEA/H/C/001014
Active substance
Caffeine citrate
International non-proprietary name (INN) or common name
caffeine
Therapeutic area (MeSH)
Apnea
Anatomical therapeutic chemical (ATC) code
N06BC01
Publication details
Marketing-authorisation holder
Chiesi Farmaceutici SpA
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
02/07/2009
Contact address
Via Palermo 26/A
IT-43100 Parma
Italy

Product information

20/11/2018 Peyona (previously Nymusa) - EMEA/H/C/001014 - N/0021

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

Treatment of primary apnoea of premature newborns.

Assessment history

How useful was this page?

Add your rating
Average
1 rating
1 rating